U.S. markets close in 57 minutes
  • S&P 500

    4,418.90
    +7.11 (+0.16%)
     
  • Dow 30

    35,121.52
    +59.97 (+0.17%)
     
  • Nasdaq

    14,838.35
    +1.36 (+0.01%)
     
  • Russell 2000

    2,214.11
    +4.46 (+0.20%)
     
  • Crude Oil

    72.18
    +0.11 (+0.15%)
     
  • Gold

    1,796.70
    -5.10 (-0.28%)
     
  • Silver

    25.25
    +0.02 (+0.07%)
     
  • EUR/USD

    1.1805
    +0.0035 (+0.30%)
     
  • 10-Yr Bond

    1.2800
    -0.0060 (-0.47%)
     
  • GBP/USD

    1.3814
    +0.0060 (+0.44%)
     
  • USD/JPY

    110.3700
    -0.1400 (-0.13%)
     
  • BTC-USD

    39,726.37
    +5,298.42 (+15.39%)
     
  • CMC Crypto 200

    942.68
    +27.19 (+2.97%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni

Biogen Inc (NASDAQ: BIIB) will miss quarterly sales expectations for its Tecfidera treatment for multiple sclerosis Friday but the disappointment shouldn't roil the company's shares, an analyst said this week.

Morgan Stanley's Matthew Harrison said Biogen in the past has proven volatile after missing Tecfidera expectations.

But Harrison said a promising outlook for Biogen's proposed Alzheimer's treatment BIIB037 "provides a new floor" that could dampen volatility.

View more earnings on BIIB

Harrison expects Biogen's overall results will meet Wall Street consensus of $3.91 a share on revenue of $2.66 billion.

But Tecfidera sales of $890 million will miss consensus expectations by about 2 percent, according to his estimate.

Separately, Harrison said Gilead Sciences, Inc. (NASDAQ: GILD)'s Harvoni treatment for hepatitis C doesn't appear threatened by recent drug trial data from Merck & Co., Inc. (NYSE: MRK).

Results from Merck's study of its grazoprevir/elbasvir hepatitis drug "continue to position Harvoni as first-in-class."

Latest Ratings for BIIB

Mar 2015

BMO Capital

Maintains

Outperform

Mar 2015

Citigroup

Maintains

Buy

Mar 2015

Stifel Nicolaus

Downgrades

Buy

Hold

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

See more from Benzinga

© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.